QNRX NASDAQ
Quoin Pharmaceuticals, Ltd.
1W: -30.5%
1M: -33.7%
3M: -2.8%
YTD: -68.2%
1Y: -38.2%
3Y: -97.0%
5Y: -100.0%
$4.47
-0.25 (-5.30%)
Weekly Expected Move ±11.0%
$3
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.5M
Congress—
ETF Holdings—
Key Statistics
Market Cap$9.0M
52W Range3.25-41.8
Volume17,120
Avg Volume542,309
Beta1.66
Dividend—
Analyst Ratings
Company Info
CEOMichael Myers
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2016-08-01
Websitequoinpharma.com
42127 Pleasant Forest Court
Ashburn, VA 20148-7349
US
Ashburn, VA 20148-7349
US
703 980 4182
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Latest News
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
What is Zacks Research’s Forecast for QNRX FY2026 Earnings?
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Carter Denise P. | P-Purchase | 20,490 | $4.88 | 2026-08-31 |
| Carter Denise P. | P-Purchase | 10,245 | $6.10 | 2026-08-31 |
| Myers Michael | P-Purchase | 20,490 | $4.88 | 2026-08-31 |
| Myers Michael | P-Purchase | 10,245 | $6.10 | 2026-08-31 |
| Lawlor Sally Bridget | P-Purchase | 10,244 | $4.88 | 2026-08-31 |